Safe Prescribing — MCQs

A 79-year-old woman with atrial fibrillation on edoxaban 60mg once daily is admitted with a fractured neck of femur requiring surgical repair. Her eGFR is 48 ml/min/1.73m². She had her last dose of edoxaban 8 hours ago. Surgery is planned for 10:00 tomorrow (26 hours after last dose). What is the most appropriate perioperative anticoagulation management?

Q202

A 44-year-old man with type 1 diabetes is admitted with severe gastroenteritis, vomiting, and diarrhoea. He is unable to eat. His capillary blood glucose is 14.2 mmol/L and ketones are 3.8 mmol/L. He normally takes insulin degludec 30 units once daily and insulin aspart with meals. What is the most appropriate management of his insulin therapy?

Q203

A 52-year-old woman with epilepsy controlled on carbamazepine 400mg twice daily is started on apixaban 5mg twice daily for newly diagnosed pulmonary embolism. After 2 weeks, she develops worsening leg swelling and breathlessness. A repeat CT pulmonary angiogram shows extension of her pulmonary embolism. What is the most likely explanation?

Q204

A 71-year-old man is admitted with an acute ST-elevation myocardial infarction and undergoes primary percutaneous coronary intervention with drug-eluting stent insertion. He has atrial fibrillation with a CHA₂DS₂-VASc score of 5. His eGFR is 55 ml/min/1.73m². What is the most appropriate antithrombotic regimen on discharge?

Q205

A 58-year-old man with newly diagnosed type 2 diabetes is started on a basal-bolus insulin regimen. He injects insulin glargine 20 units at 22:00 and insulin lispro 6 units before each meal. He works shifts including night shifts. On a night shift week, he sleeps from 08:00 to 16:00 and has his main meal at 17:00 and 02:00. How should he adjust his basal insulin timing?

Q206

A 63-year-old woman with rheumatoid arthritis is started on methotrexate 15mg once weekly. Which of the following monitoring schedules is recommended for the first 6 months of treatment?

Q207

A 76-year-old man on warfarin for atrial fibrillation (target INR 2-3) presents with INR of 6.8. He has no evidence of bleeding but reports taking antibiotics from his dentist 3 days ago for a tooth infection. His regular warfarin dose is 5mg daily. What is the most appropriate immediate management?

Q208

What is the recommended frequency for monitoring lithium levels in a patient who has been on a stable dose of lithium carbonate for 2 years with consistently therapeutic levels and no intercurrent illness?

Q209

A 33-year-old woman with type 1 diabetes on basal-bolus insulin therapy is planning conception. Her current HbA1c is 58 mmol/mol (7.5%). She is on insulin detemir 22 units at bedtime and insulin aspart before meals. She also takes atorvastatin 20mg daily and ramipril 5mg daily for microalbuminuria. What is the most important prescribing change before conception?

Q210

A 69-year-old woman with chronic kidney disease stage 4 (eGFR 22 ml/min/1.73m²) requires anticoagulation for newly diagnosed atrial fibrillation. Her CHA₂DS₂-VASc score is 4 and HAS-BLED score is 2. She weighs 58 kg. Which anticoagulant and dose is most appropriate?

Safe Prescribing UK Medical PG Practice Questions and MCQs

Question 201: A 79-year-old woman with atrial fibrillation on edoxaban 60mg once daily is admitted with a fractured neck of femur requiring surgical repair. Her eGFR is 48 ml/min/1.73m². She had her last dose of edoxaban 8 hours ago. Surgery is planned for 10:00 tomorrow (26 hours after last dose). What is the most appropriate perioperative anticoagulation management?

A. Proceed with surgery at 10:00 tomorrow and restart edoxaban 6 hours post-operatively
B. Delay surgery for a further 24 hours, proceed at 50 hours after last edoxaban dose
C. Bridge with therapeutic low molecular weight heparin until 12 hours before surgery
D. Give prothrombin complex concentrate pre-operatively to reverse edoxaban
E. Proceed with surgery at 10:00 tomorrow and restart edoxaban 48-72 hours post-operatively depending on haemostasis (Correct Answer)

Explanation: ***Proceed with surgery at 10:00 tomorrow and restart edoxaban 48-72 hours post-operatively depending on haemostasis*** - The 26-hour hold before surgery allows for sufficient **edoxaban** clearance, as approximately two half-lives (average 10-14 hours) would have passed, significantly reducing drug levels, which is appropriate for **urgent femur fracture repair** given an **eGFR of 48 ml/min**. - Restarting **edoxaban** should be delayed for **48–72 hours** after major orthopaedic surgery like a **femur fracture repair** to ensure reliable **haemostasis** and minimize the risk of serious post-operative bleeding or hematoma formation. *Proceed with surgery at 10:00 tomorrow and restart edoxaban 6 hours post-operatively* - Restarting a full-dose **DOAC** only **6 hours** after major orthopaedic surgery carries a very high risk of **post-operative bleeding** due to the rapid onset of its anticoagulant effect. - Guidelines for high-bleeding-risk surgery typically recommend delaying DOAC restart for at least **48-72 hours** to allow for initial surgical site healing and stable **haemostasis**. *Delay surgery for a further 24 hours, proceed at 50 hours after last edoxaban dose* - Undue delay of **hip fracture surgery** beyond 36-48 hours is associated with increased **mortality** and a higher incidence of complications like **pneumonia**, **pressure ulcers**, and functional decline in elderly patients. - A 26-hour hold is generally considered adequate for this type of urgent surgery in a patient with moderate renal impairment, making further delay medically unnecessary and potentially harmful. *Bridge with therapeutic low molecular weight heparin until 12 hours before surgery* - **Bridging anticoagulation** with LMWH is generally **not recommended** for patients on **DOACs** undergoing surgery, as it increases the risk of **perioperative bleeding** without offering superior antithrombotic protection. - The predictable offset and rapid onset of **DOACs** mean a simple withholding strategy is preferred, avoiding the added complexity and bleeding risk of LMWH. *Give prothrombin complex concentrate pre-operatively to reverse edoxaban* - **Prothrombin complex concentrate (PCC)** or specific reversal agents are reserved for situations of **life-threatening bleeding** or highly emergent surgery where delay is not possible. - This **femur fracture repair** is urgent but allows for a planned delay of 26 hours, making a waiting strategy safer and more appropriate than immediate pharmacological **anticoagulation reversal**, which has its own risks and high costs.

Question 202: A 44-year-old man with type 1 diabetes is admitted with severe gastroenteritis, vomiting, and diarrhoea. He is unable to eat. His capillary blood glucose is 14.2 mmol/L and ketones are 3.8 mmol/L. He normally takes insulin degludec 30 units once daily and insulin aspart with meals. What is the most appropriate management of his insulin therapy?

A. Stop all insulin until he is able to eat and drink normally
B. Continue insulin degludec at usual dose, stop insulin aspart, and start variable rate intravenous insulin infusion (Correct Answer)
C. Stop insulin degludec, stop insulin aspart, and start variable rate intravenous insulin infusion
D. Reduce insulin degludec to 50% of normal dose and stop insulin aspart
E. Continue insulin degludec at usual dose, give reduced dose insulin aspart with any food intake, and monitor closely

Explanation: ***Continue insulin degludec at usual dose, stop insulin aspart, and start variable rate intravenous insulin infusion*** - This patient is in **Diabetic Ketoacidosis (DKA)**, evidenced by significant ketonemia (3.8 mmol/L) and hyperglycemia (14.2 mmol/L); management requires a **Variable Rate Intravenous Insulin Infusion (VRIII)** to precisely control glucose and ketones. - In **Type 1 diabetes**, **basal insulin** (Degludec) should generally be continued alongside VRIII to prevent **rebound ketosis** and facilitate a smooth transition off IV insulin once DKA resolves. Mealtime insulin (Aspart) is stopped as he cannot eat. *Stop all insulin until he is able to eat and drink normally* - Stopping all insulin in a **Type 1 diabetic** with ketosis is dangerous, as it leads to absolute insulin deficiency and rapid worsening of **metabolic acidosis** and DKA. - **Sick day rules** for Type 1 diabetes strongly advise against discontinuing all insulin, even during illness or inability to eat, to prevent severe ketosis. *Stop insulin degludec, stop insulin aspart, and start variable rate intravenous insulin infusion* - Discontinuing **long-acting basal insulin** (Degludec) while on VRIII increases the risk of **rebound hyperglycemia** and ketosis, especially when transitioning back to subcutaneous insulin. - Maintaining basal insulin provides essential background coverage, crucial for suppressing **ketogenesis** and stabilizing blood glucose throughout the DKA resolution process. *Reduce insulin degludec to 50% of normal dose and stop insulin aspart* - In the context of **DKA** and acute illness, the body's stress response typically *increases* insulin requirements, making a 50% reduction in basal insulin insufficient and potentially harmful. - This approach does not address the acute need for **intravenous insulin therapy** to rapidly reverse the established DKA and metabolic acidosis. *Continue insulin degludec at usual dose, give reduced dose insulin aspart with any food intake, and monitor closely* - This strategy is inadequate for a patient with established **DKA** who is unable to eat or drink; it lacks the necessary rapid and precise glucose and ketone control offered by IV insulin. - Giving **insulin aspart** with "any food intake" is impractical given the patient's severe vomiting and inability to tolerate oral intake, making bolus insulin ineffective and potentially risky.

Question 203: A 52-year-old woman with epilepsy controlled on carbamazepine 400mg twice daily is started on apixaban 5mg twice daily for newly diagnosed pulmonary embolism. After 2 weeks, she develops worsening leg swelling and breathlessness. A repeat CT pulmonary angiogram shows extension of her pulmonary embolism. What is the most likely explanation?

A. Apixaban underdosing due to her weight exceeding 120kg
B. Apixaban resistance due to factor V Leiden mutation
C. Reduced apixaban levels due to enzyme induction by carbamazepine (Correct Answer)
D. Inadequate treatment duration with only 2 weeks of anticoagulation
E. Development of heparin-induced thrombocytopenia from bridging therapy

Explanation: ***Reduced apixaban levels due to enzyme induction by carbamazepine***- **Carbamazepine** is a potent inducer of **CYP3A4** and **P-glycoprotein (P-gp)**, significantly increasing the metabolism and clearance of **apixaban**.- This **drug-drug interaction** leads to sub-therapeutic plasma concentrations of apixaban, resulting in **treatment failure** and extension of the pulmonary embolism.*Apixaban underdosing due to her weight exceeding 120kg*- Although extreme body weight can influence **DOAC** pharmacokinetics, the patient's weight is not provided, making this speculative.- The direct and significant interaction of **carbamazepine** as an enzyme inducer is a more probable and medically established explanation for therapeutic failure.*Apixaban resistance due to factor V Leiden mutation*- **Factor V Leiden** is a thrombophilia causing resistance to **activated protein C**, not direct oral anticoagulants like **apixaban**, which targets **Factor Xa**.- Genetic thrombophilias are underlying risk factors for clotting, not mechanisms of 'resistance' to the direct action of a specific anticoagulant.*Inadequate treatment duration with only 2 weeks of anticoagulation*- Two weeks is generally sufficient time for **apixaban** to achieve steady-state therapeutic levels and prevent clot extension.- The **extension** of the pulmonary embolism while on treatment indicates a failure of drug efficacy rather than an insufficient duration of therapy.*Development of heparin-induced thrombocytopenia from bridging therapy*- **Heparin-induced thrombocytopenia (HIT)** requires prior exposure to **heparin**, which is not mentioned in the patient's history.- **Apixaban** is a direct Factor Xa inhibitor and does not cause HIT; it is often used as an alternative anticoagulant in HIT.

Question 204: A 71-year-old man is admitted with an acute ST-elevation myocardial infarction and undergoes primary percutaneous coronary intervention with drug-eluting stent insertion. He has atrial fibrillation with a CHA₂DS₂-VASc score of 5. His eGFR is 55 ml/min/1.73m². What is the most appropriate antithrombotic regimen on discharge?

A. Aspirin 75mg, clopidogrel 75mg, and apixaban 5mg twice daily (triple therapy) (Correct Answer)
B. Aspirin 75mg and rivaroxaban 20mg once daily (dual therapy)
C. Aspirin 75mg, clopidogrel 75mg, and warfarin with target INR 2-3 (triple therapy)
D. Clopidogrel 75mg and apixaban 5mg twice daily (dual therapy) after 1 week of triple therapy
E. Aspirin 75mg, ticagrelor 90mg twice daily, and apixaban 2.5mg twice daily (triple therapy)

Explanation: ***Aspirin 75mg, clopidogrel 75mg, and apixaban 5mg twice daily (triple therapy)***- Patients with **atrial fibrillation** (CHA₂DS₂-VASc score 5) undergoing PCI for **STEMI** with DES insertion require **triple therapy** (aspirin, clopidogrel, and a DOAC) for an initial duration (typically 1 week to 1 month) to prevent both stent thrombosis and embolic stroke.- **Apixaban 5mg twice daily** is the standard dose as this patient (71 years old, eGFR 55 ml/min/1.73m²) does not meet two or more dose-reduction criteria (age ≥80, weight ≤60kg, or creatinine ≥1.5 mg/dL). *Aspirin 75mg and rivaroxaban 20mg once daily (dual therapy)*- This regimen lacks a **P2Y12 inhibitor**, which is mandatory immediately following **acute coronary syndrome (ACS)** and stent insertion to prevent acute stent thrombosis.- **Triple therapy** is the preferred initial discharge strategy for a patient with a high-risk event like STEMI and AF before transitioning to dual therapy. *Aspirin 75mg, clopidogrel 75mg, and warfarin with target INR 2-3 (triple therapy)*- Current guidelines prefer **DOACs** over **warfarin** in triple therapy regimens due to a significantly lower risk of **intracranial hemorrhage** and major bleeding.- Warfarin should generally only be used for triple therapy if there is a specific contraindication to DOACs, such as a **mechanical heart valve**. *Clopidogrel 75mg and apixaban 5mg twice daily (dual therapy) after 1 week of triple therapy*- While transitioning to **dual therapy** (DOAC + single antiplatelet) is a valid long-term strategy, the standard discharge instruction for an acute STEMI with high ischemic risk usually involves a defined period of **triple therapy**.- This option describes a step-down approach; however, for the immediate **discharge** after STEMI-related PCI, triple therapy remains the primary recommendation for the initial phase. *Aspirin 75mg, ticagrelor 90mg twice daily, and apixaban 2.5mg twice daily (triple therapy)*- **Ticagrelor** is generally avoided in triple therapy due to a significantly increased **bleeding risk**; **clopidogrel** is the P2Y12 inhibitor of choice when combined with anticoagulants.- **Apixaban 2.5mg twice daily** is an under-dose for this patient as he does not meet the specified clinical or biochemical criteria for dose reduction.

Question 205: A 58-year-old man with newly diagnosed type 2 diabetes is started on a basal-bolus insulin regimen. He injects insulin glargine 20 units at 22:00 and insulin lispro 6 units before each meal. He works shifts including night shifts. On a night shift week, he sleeps from 08:00 to 16:00 and has his main meal at 17:00 and 02:00. How should he adjust his basal insulin timing?

A. Continue glargine at 22:00 regardless of sleep pattern to maintain consistency (Correct Answer)
B. Take glargine at 08:00 (bedtime during night shifts) and 22:00 (bedtime during day shifts)
C. Take glargine at the same time each day (e.g., 22:00) but reduce dose by 20% on night shifts
D. Take glargine upon waking regardless of the time to maintain consistent post-sleep timing
E. Switch to twice-daily intermediate-acting insulin to provide more flexibility

Explanation: ***Continue glargine at 22:00 regardless of sleep pattern to maintain consistency*** - **Insulin glargine** is a **long-acting basal insulin** with a **24-hour duration** and no significant peak, meaning it should be administered at the same **clock time** every day to maintain a consistent background insulin level. - For shift workers, keeping the basal timing constant prevents **insulin stacking** (causing hypoglycemia) or **gaps** in coverage (causing hyperglycemia) that would occur if the timing shifted with sleep cycles, which helps maintain stable glycemic control. *Take glargine at 08:00 (bedtime during night shifts) and 22:00 (bedtime during day shifts)* - Shifting administration times by a large interval (e.g., 14 hours) based on sleep patterns would disrupt the **pharmacokinetic steady state** of long-acting insulin. - This approach would lead to unpredictable periods of either **excessive insulin levels** (if doses are too close) or **insulin deficiency** (if doses are too far apart), both detrimental to glucose management. *Take glargine at the same time each day (e.g., 22:00) but reduce dose by 20% on night shifts* - There is no general clinical indication that **metabolic basal insulin requirements** significantly decrease during night shifts compared to day shifts. - Arbitrarily reducing the dose can lead to **hyperglycemia** and poor glycemic control; any dose adjustments should be based on **blood glucose monitoring trends** and physician guidance. *Take glargine upon waking regardless of the time to maintain consistent post-sleep timing* - Administering **long-acting basal insulin** at variable times each day based on waking disrupts its consistent 24-hour action, making it difficult to predict its effect. - Only **bolus insulin (lispro)** should be adjusted based on meal timing and activity, while basal insulin provides a steady background. *Switch to twice-daily intermediate-acting insulin to provide more flexibility* - **Intermediate-acting insulins (like NPH)** have more pronounced **peaks** and shorter durations, making them **less flexible** and more prone to causing **hypoglycemia** during shift changes. - The current **basal-bolus regimen** using glargine is generally preferred for shift workers due to its stable, peakless profile and the ability to adjust mealtime boluses independently.

Question 206: A 63-year-old woman with rheumatoid arthritis is started on methotrexate 15mg once weekly. Which of the following monitoring schedules is recommended for the first 6 months of treatment?

A. Full blood count and liver function tests weekly for 6 weeks, then monthly
B. Full blood count and liver function tests every 2 weeks until stable for 6 weeks, then every 2-3 months
C. Full blood count, liver function tests and renal function every 2 weeks until stable for 6 weeks, then monthly for 3 months, then every 3 months (Correct Answer)
D. Full blood count and liver function tests monthly for 3 months, then every 3 months
E. Full blood count, liver function tests and renal function at baseline, 1 month, 3 months, and 6 months

Explanation: ***Full blood count, liver function tests and renal function every 2 weeks until stable for 6 weeks, then monthly for 3 months, then every 3 months***- This schedule aligns with **NICE** and **BSR guidelines** for **methotrexate monitoring**, effectively checking for **myelosuppression**, **hepatotoxicity**, and **renal impairment** during the critical initiation phase.- Including **renal function (U&Es)** is paramount because methotrexate is primarily **renally excreted**, and impaired kidney function significantly elevates the risk of drug toxicity.*Full blood count and liver function tests weekly for 6 weeks, then monthly*- While rigorous, **weekly monitoring** for 6 weeks is generally considered **overly frequent** and not standard practice, making it less practical for routine outpatient management.- This option critically **omits regular renal function monitoring**, which is an essential part of safe methotrexate prescribing due to its renal excretion.*Full blood count and liver function tests every 2 weeks until stable for 6 weeks, then every 2-3 months*- This monitoring schedule lacks the crucial **intermediate monthly monitoring phase** (typically for 3 months) that bridges initial stabilization and long-term maintenance.- Similar to other incorrect options, it fails to include **renal function (U&Es)** assessment, focusing only on blood counts and liver enzymes.*Full blood count and liver function tests monthly for 3 months, then every 3 months*- Starting with **monthly monitoring** is **insufficiently frequent** for newly initiated methotrexate, as rapid toxicities like **pancytopenia** can develop within the first few weeks.- This option also completely misses the requirement for **renal function** evaluation, which is vital for monitoring methotrexate clearance and preventing accumulation.*Full blood count, liver function tests and renal function at baseline, 1 month, 3 months, and 6 months*- This frequency of monitoring is **too sparse** to detect early adverse effects or idiosyncratic reactions, which often manifest shortly after starting methotrexate or adjusting its dose.- Guidelines mandate more frequent initial checks (e.g., bi-weekly) to ensure **patient safety** and allow for timely intervention or adjustment of the methotrexate regimen.

Question 207: A 76-year-old man on warfarin for atrial fibrillation (target INR 2-3) presents with INR of 6.8. He has no evidence of bleeding but reports taking antibiotics from his dentist 3 days ago for a tooth infection. His regular warfarin dose is 5mg daily. What is the most appropriate immediate management?

A. Give oral vitamin K 1-5mg and withhold 1-2 doses of warfarin, recheck INR in 24 hours (Correct Answer)
B. Give intravenous vitamin K 10mg and admit for observation
C. Withhold warfarin for 2 days and recheck INR without giving vitamin K
D. Give prothrombin complex concentrate and vitamin K 5mg IV
E. Continue warfarin at reduced dose of 2.5mg and recheck INR in 3 days

Explanation: ***Give oral vitamin K 1-5mg and withhold 1-2 doses of warfarin, recheck INR in 24 hours*** - For an **INR between 5.0 and 8.0** in a patient with **no bleeding** but additional risk factors (such as **age >70**), consensus guidelines recommend withholding warfarin and administering **low-dose oral Vitamin K**. - This approach ensures a controlled reduction of the INR within 24 hours without causing **warfarin resistance** upon re-initiation. *Give intravenous vitamin K 10mg and admit for observation* - High-dose **intravenous Vitamin K** is reserved for patients with **major bleeding** or extremely high INR levels to achieve rapid reversal. - Over-correction with 10mg IV can lead to **prolonged resistance** to warfarin therapy, complicating subsequent management of his atrial fibrillation. *Withhold warfarin for 2 days and recheck INR without giving vitamin K* - Simply **withholding doses** is typically reserved for an INR <5.0; at 6.8 with the patient's **advanced age**, more active management is needed to prevent hemorrhage. - Without Vitamin K, the INR may take too long to return to the **therapeutic range**, increasing the window of risk for a spontaneous bleed. *Give prothrombin complex concentrate and vitamin K 5mg IV* - **Prothrombin complex concentrate (PCC)** is the gold standard for **emergency reversal** of warfarin in the setting of life-threatening or **major bleeding**. - This patient is **hemodynamically stable** with no clinical bleeding, making the use of blood products unnecessary and clinically inappropriate. *Continue warfarin at reduced dose of 2.5mg and recheck INR in 3 days* - Continuing warfarin when the INR is significantly **above the therapeutic threshold (6.8)** poses a dangerous risk of intracranial or gastrointestinal hemorrhage. - Direct **drug-drug interactions** with the dentist's antibiotics (likely **metronidazole or erythromycin**) necessitate immediate cessation until the INR stabilizes.

Question 208: What is the recommended frequency for monitoring lithium levels in a patient who has been on a stable dose of lithium carbonate for 2 years with consistently therapeutic levels and no intercurrent illness?

A. Every month
B. Every 3 months (Correct Answer)
C. Every 6 months
D. Every 12 months
E. Only when clinically indicated

Explanation: ***Every 3 months*** - According to **NICE guidelines** and the **BNF**, lithium levels should be monitored every 3 months for patients on a stable dose of lithium for more than one year. - This frequency is necessary due to lithium's **narrow therapeutic index** (0.4–1.0 mmol/L) and the risk of toxicity from changes in **renal function** or fluid balance. *Every month* - Monthly monitoring is typically reserved for the **initiation phase** of treatment or during **dose titration** until therapeutic levels are stabilized. - It is not required for a patient who has been clinically stable and compliant on the same dose for **two years**. *Every 6 months* - While some stable patients under 65 may have monitoring extended under specific specialist guidance, the **standard protocol** remains every 3 months for long-term safety. - Waiting 6 months may delay the detection of a decline in **eGFR** or changes in serum levels, risking **lithium toxicity**. *Every 12 months* - An annual check is insufficient for monitoring serum levels because lithium concentrations can fluctuate significantly with **dietary salt**, hydration, or **NSAID use**. - Yearly monitoring applies to other parameters like **serum calcium**, but not to the serum lithium concentration itself. *Only when clinically indicated* - This approach is dangerous because lithium toxicity can develop **insidiously** without obvious external triggers. - Routine **proactive monitoring** is mandatory to prevent irreversible **nephrotoxicity** and thyroid dysfunction associated with long-term use.

Question 209: A 33-year-old woman with type 1 diabetes on basal-bolus insulin therapy is planning conception. Her current HbA1c is 58 mmol/mol (7.5%). She is on insulin detemir 22 units at bedtime and insulin aspart before meals. She also takes atorvastatin 20mg daily and ramipril 5mg daily for microalbuminuria. What is the most important prescribing change before conception?

A. Switch to insulin pump therapy to optimise glucose control
B. Stop ramipril and switch to labetalol or nifedipine (Correct Answer)
C. Increase insulin doses by 25% in preparation for pregnancy
D. Switch atorvastatin to a fibrate for lipid management
E. Add high-dose folic acid 5mg daily

Explanation: ***Stop ramipril and switch to labetalol or nifedipine*** - **ACE inhibitors** like ramipril are strictly **teratogenic**, especially in the second and third trimesters, causing **fetal renal dysgenesis**, skull hypoplasia, and **oligohydramnios**. - Transitioning to pregnancy-safe alternatives like **labetalol** or **nifedipine** is the most critical step to prevent major congenital malformations once conception occurs.*Switch to insulin pump therapy to optimise glucose control* - While an **insulin pump (CSII)** can improve glycemic control, it is not a mandatory requirement if the patient can achieve targets with **basal-bolus therapy**. - Optimization of the **HbA1c** (target <48 mmol/mol) is important, but discontinuing known **teratogens** takes immediate priority over changing the delivery method.*Increase insulin doses by 25% in preparation for pregnancy* - Insulin resistance typically increases during the **second and third trimesters**, not necessarily during the pre-conception phase. - Doses should be titrated based on **self-monitoring of blood glucose** rather than a preemptive fixed percentage increase, which could risk **hypoglycemia**.*Switch atorvastatin to a fibrate for lipid management* - Both **statins** and **fibrates** are generally avoided in pregnancy; statins are contraindicated due to potential interference with **fetal cholesterol synthesis**. - Standard practice is to **discontinue lipid-lowering therapy** entirely before conception as the risk of short-term hyperlipidemia is outweighed by fetal safety.*Add high-dose folic acid 5mg daily* - Women with diabetes are indeed recommended to take **5mg folic acid** to reduce the risk of **neural tube defects**. - While essential, the active cessation of a known **fetotoxic drug** like an ACE inhibitor is considered the most urgent safety intervention in pre-pregnancy counseling.

Question 210: A 69-year-old woman with chronic kidney disease stage 4 (eGFR 22 ml/min/1.73m²) requires anticoagulation for newly diagnosed atrial fibrillation. Her CHA₂DS₂-VASc score is 4 and HAS-BLED score is 2. She weighs 58 kg. Which anticoagulant and dose is most appropriate?

A. Apixaban 5mg twice daily
B. Apixaban 2.5mg twice daily (Correct Answer)
C. Rivaroxaban 20mg once daily
D. Dabigatran 110mg twice daily
E. Warfarin with target INR 2-3

Explanation: ***Apixaban 2.5mg twice daily*** - Dose reduction of **Apixaban** to 2.5mg twice daily is required if two of three criteria are met: **age ≥80**, **body weight ≤60 kg**, or **serum creatinine ≥133 μmol/L** (this patient meets weight and creatinine criteria). - **Apixaban** is generally preferred over other NOACs in **Severe Chronic Kidney Disease (Stage 4)** due to its lower renal clearance profile and reduced risk of major bleeding. *Apixaban 5mg twice daily* - This is the standard dose and would be considered **overdosing** in this patient given she meets the criteria for dose reduction (weight <60kg and low eGFR). - Using the full dose in this clinical scenario significantly increases the **hemorrhagic risk** without providing additional stroke protection. *Rivaroxaban 20mg once daily* - The standard 20mg dose is contraindicated in patients with an **eGFR <50 ml/min**, as it would lead to drug accumulation. - Even at a reduced dose of 15mg, **Rivaroxaban** is less established than apixaban in managing patients with severe renal impairment nearing **ESRD**. *Dabigatran 110mg twice daily* - **Dabigatran** is contra-indicated when the **eGFR is <30 ml/min** because it is primarily excreted (80%) by the kidneys. - Use in this patient would lead to a high risk of **toxicity** and life-threatening bleeding complications due to profound drug accumulation. *Warfarin with target INR 2-3* - While **Warfarin** can be used in renal failure, it is associated with a higher risk of **intracranial hemorrhage** and vascular calcification compared to apixaban. - Monitoring is more difficult in **CKD** patients, and recent evidence favors dose-adjusted **Apixaban** for its superior safety profile in Stage 4 disease.

Practice by Chapter

Anticoagulant safety

Practice Questions

High-risk medicines

Practice Questions

Insulin safety

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free